Department of Surgery and Cancer, Imperial College London, St Mary's Hospital, London, UK.
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):430-440. doi: 10.1038/s41575-020-0290-z. Epub 2020 Apr 8.
The global numbers of robotic gastrointestinal surgeries are increasing. However, the evidence base for robotic gastrointestinal surgery does not yet support its widespread adoption or justify its cost. The reasons for its continued popularity are complex, but a notable driver is the push for innovation - robotic surgery is seen as a compelling solution for delivering on the promise of minimally invasive precision surgery - and a changing commercial landscape delivers the promise of increased affordability. Novel systems will leverage the robot as a data-driven platform, integrating advances in imaging, artificial intelligence and machine learning for decision support. However, if this vision is to be realized, lessons must be heeded from current clinical trials and translational strategies, which have failed to demonstrate patient benefit. In this Perspective, we critically appraise current research to define the principles on which the next generation of gastrointestinal robotics trials should be based. We also discuss the emerging commercial landscape and define existing and new technologies.
全球机器人胃肠道手术的数量正在增加。然而,机器人胃肠道手术的证据基础尚不足以支持其广泛采用或证明其成本合理。其持续流行的原因很复杂,但一个值得注意的驱动因素是对创新的推动——机器人手术被视为实现微创精准手术承诺的一种引人注目的解决方案——而不断变化的商业环境带来了增加可负担性的承诺。新型系统将利用机器人作为数据驱动的平台,将成像、人工智能和机器学习方面的进展集成到决策支持中。然而,如果要实现这一愿景,就必须从目前临床试验和转化策略中吸取教训,这些临床试验和转化策略未能证明患者受益。在本观点中,我们批判性地评估了当前的研究,以确定下一代胃肠道机器人试验应该基于的原则。我们还讨论了新兴的商业环境,并定义了现有和新技术。